FY2018 EPS Estimates for Amgen Inc. Decreased by Analyst (AMGN)
Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Leerink Swann decreased their FY2018 earnings per share (EPS) estimates for shares of Amgen in a report issued on Monday. Leerink Swann analyst G. Porges now expects that the medical research company will post earnings per share of $12.74 for the year, down from their previous forecast of $12.76. Leerink Swann has a “Market Perform” rating and a $161.00 price objective on the stock. Leerink Swann also issued estimates for Amgen’s FY2019 earnings at $12.59 EPS, FY2020 earnings at $12.45 EPS and FY2021 earnings at $12.39 EPS.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.84 EPS. TRADEMARK VIOLATION NOTICE: “FY2018 EPS Estimates for Amgen Inc. Decreased by Analyst (AMGN)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/10/18/fy2018-eps-estimates-for-amgen-inc-decreased-by-analyst-amgn.html.
Several other analysts have also recently weighed in on the company. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $189.00 price objective on shares of Amgen in a report on Friday, June 30th. BidaskClub raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Credit Suisse Group set a $177.00 price objective on Amgen and gave the stock a “hold” rating in a report on Friday, July 14th. Bank of America Corporation boosted their price objective on Amgen to $210.00 and gave the stock a “buy” rating in a report on Thursday, October 5th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and issued a $174.00 price target (up from $172.00) on shares of Amgen in a research note on Wednesday, July 26th. Twelve research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $189.99.
Shares of Amgen (AMGN) traded up 0.15% during trading on Wednesday, hitting $186.47. 1,523,862 shares of the stock traded hands. Amgen has a 1-year low of $133.64 and a 1-year high of $191.10. The company has a 50 day moving average of $183.93 and a 200-day moving average of $170.98. The company has a market cap of $136.06 billion, a PE ratio of 16.98 and a beta of 1.36.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jackson Grant Investment Advisers Inc. boosted its holdings in shares of Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the last quarter. Financial Advisory Service Inc. boosted its holdings in shares of Amgen by 0.3% in the 2nd quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock valued at $340,000 after buying an additional 5 shares during the last quarter. Capital Advisors Ltd. LLC boosted its holdings in shares of Amgen by 0.6% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock valued at $190,000 after buying an additional 7 shares during the last quarter. Ballentine Partners LLC boosted its holdings in shares of Amgen by 0.3% in the 2nd quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock valued at $620,000 after buying an additional 9 shares during the last quarter. Finally, Hudock Capital Group LLC boosted its holdings in shares of Amgen by 0.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock valued at $330,000 after buying an additional 10 shares during the last quarter. 78.08% of the stock is owned by institutional investors.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.19% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.